Back to Journals » OncoTargets and Therapy » Volume 15

RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum]

Authors Zhang X, Song Y , Song N, Zhang Y, Zhang L, Wang Y, Wang Z, Qu X, Liu Y 

Received 19 April 2022

Accepted for publication 19 April 2022

Published 13 May 2022 Volume 2022:15 Pages 529—530

DOI https://doi.org/10.2147/OTT.S371401



Zhang X, Song Y, Song N, et al. Onco Targets Ther. 2017;10:73–83.

In a detailed re-analyses of the data post-publication, the authors found the incorrect images were used for Figure 5A on page 80. Due to an error at the time of figure assembly the images from 5B was used as a placeholder and not replaced later. The correct Figure 5 is shown in Download Article.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

 

 

Read the original article

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.